Safety evaluations
toxicity, Toxicities
ADVERSE EVENT
A cycle was defined as a period of 4 weeks or 28 days. Safety assessments including complete blood counts, serum chemistries, liver enzymes and toxicity evaluations were completed at baseline, day 1 and 15 of cycle 1, and then day 1 of every cycle thereafter. Toxicities were evaluated and graded using the CTEP NCI Common Terminology Criteria for Adverse Events (CTCAE), version 4.0. All patients were evaluable for toxicity from the time of their first treatment of riluzole and sorafenib.